Investor Presentaiton
ORIENT-32 (1L HCC): Global First PD-1 Combination Study
that Met Primary Endpoints
Overall Survival (%)
100
75
50
OS
62.4%
48.5%
Arms
Events, n (%)
25
Median OS (mo)
(95% CI)
HR
P value ab
(95% CI)*
Sin + Bev
122 (32.1)
NE (NE, NE)
<0.0001
0.569
(0.431, 0.751)
Sor
87 (45.5)
10.4 (8.5, NE)
Progression-free Survival (%)
PFS (by IRRC)
Arms
Events, n (%)
Median PFS (mo)
(95% CI)
P value & b
HR
(95% CI)*
Sin + Bev
245 (64.5)
4.6 (4.1, 5.7)
0.565
<0.0001
(0.455, 0.701)
Sor
142 (74.3)
2.8 (2.7, 3.2)
43.6%
32.7%
19.5%
M
AMA
:11.6%
0
2
4
6
8
Months
10
12
14
16
0
2
4
6
8
10
12
14
Months
Number at risk
Sin + Bev
380
372
351
Sor
191
175
153
314
132
235
95
126
50
52
57
11
22
2
0
0
Number at risk
SinBev 380
Sor 191
267
111
197
55
144
89
37
7
24
13
4
1
0
Sintilimab in combination with BYVASDAⓇ (bevacizumab biosimilar): the global first PD-1 combo study that met primary
endpoints with significant improvement in both OS and PFS for 1L HCC
Proffered Paper presentation
VIRTUAL
2020
ESMO
ASIA
at the ESMO Asia Virtual Congress 2020
ESMO ASIA 2020 VIRTUAL
Innovent
20-22 NOVEMBER 2020
Confidential
Copyright©2021 Innovent Biologics
21
24View entire presentation